Advanced search

729 Results

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation	05-21	BU
FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	05-21	GL
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial -- Update	05-16	DJ
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial	05-16	DJ
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity	05-16	BU
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity	05-16	GL
Roche: positive CHMP opinion for Alecensa	04-26	CF
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer	04-19	GL
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer	04-18	BU
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS	04-17	BU
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS	04-17	GL
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study	04-15	BU
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study	04-15	GL
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension	04-08	AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	03-06	AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care	03-05	GL
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies	02-25	BU
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies	02-25	GL
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	02-19	AQ
Roche: FDA approves allergy treatment	02-16	CF
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	02-16	GL
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies	02-16	BU
New long-term data for Roche's Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)	02-01	AQ
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)	02-01	BU
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)	02-01	GL
Roche cancer immunotherapy receives new EU approval	01-16	AQ
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types	01-16	GL
FDA grants priority review to omalizumab for food allergies	12-20	AQ
Roche - FDA grants priority review to Xolair for children and adults with food allergies based on positive National Institutes of Health phase III study results	12-20	AQ
Roche's Xolair Granted FDA Priority Review	12-19	DJ
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results	12-19	GL
FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results	12-19	BU
New data for Roche s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma	12-12	AQ
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma	12-11	GL
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma	12-10	BU
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A	12-09	AQ
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A	12-09	BU
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A	12-09	GL
Roche's Inavolisib Breast Cancer Drug Gets Positive Results	12-08	DJ
Roche: positive data for Kadcyla in breast cancer	12-08	CF
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment	12-08	GL
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	12-08	GL
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment	12-08	BU
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	12-08	BU
Roche to advance novel obesity and diabetes treatments	12-05	AQ
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	12-05	GL
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	12-05	BU
Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in Bet on Obesity Treatments -- Update	12-04	DJ
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes	12-04	GL
CHMP recommends new immunotherapy delivery method	11-15	AQ

No results for this search

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer